ACG: No Increased Risk of Esophageal Cancer with Oral Bisphosphonates

Share this content:
(ChemotherapyAdvisor) – Use of oral bisphosphonates did not increase risk of esophageal cancer at the population level, according to results of a study presented at the American College of Gastroenterology's 77th Annual Scientific Meeting in Las Vegas, NV.

Oral bisphosphonates, widely used to prevent and treat osteoporosis, can cause erosive esophagitis and delay healing, and some reports indicate chronic use may increase risk of esophageal cancer. However, studies evaluating this relationship are conflicting, prompting a meta-analysis of six observational studies that included 3,570 patients with esophageal cancer, conducted by Saowanee Ngamruengphong, MD, of Mayo Clinic Florida, Jacksonville, FL, and colleagues.

Of the six studies, five were performed in Western countries and one in Taiwan. Among patients who used bisphosphonates, the pooled OR for esophageal cancer was 1.02 (95%CI, 0.73–1.42), with no significant heterogeneity between studies (P=0.15).

“The pooled OR of the case control studies was marginally significant (OR 1.28; 95% CI, 1.01–1.63). Otherwise, we did not find any major changes in direction and magnitude of the summary estimates and p value of heterogeneity,” they concluded.

Abstract (select Oral & Posters, Browse by Number and select Abstract Number P577)

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs